Risper >About Rispofren
Rispofren 1 mg daily has shown success in some studies for 6 months to 2 years duration, although it must be explained to the patient at the outset that this is an antipsychotic medication, but is being used in much lower doses than normal. Amisulpride may have the same effect with a better side-effect profile. Coexistent affective disease can occur, so if the patient will not engage with an antipsychotic, an SSRI can be tried instead. An occasional feature of these cases is that the problems in the sufferer can result in other members of the household presenting with similar symptoms and in these circumstances the family members should be treated with emollients.
Rispofren is rapidly distributed. The volume of distribution is 1-2 L/kg. In plasma, Rispofren is bound to albumin and α1-acid glycoprotein. The plasma protein binding of Rispofren is 90%, and that of its major metabolite, 9-hydroxyRispofren, is 77%. Neither Rispofren nor 9-hydroxyRispofren displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10mcg/mL) caused only a slight increase in the free fraction of Rispofren at 10 ng/mL and 9-hydroxyRispofren at 50 ng/mL, changes of unknown clinical significance.
Before taking Rispofren
Some medicines are not suitable for people with certain conditions, and sometimes a medicine may only be used if extra care is taken. For these reasons, before you start taking Rispofren it is important that your doctor knows:
- If you are pregnant or breast-feeding.
- If you have a heart condition or blood vessel disease.
- If you have liver, k >
Mechanism Of Action
The mechanism of action of RISPERDAL®, in schizophrenia, is unknown. However, it has been proposed that the drug's therapeutic activity in schizophrenia could be mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism. The clinical effect from RISPERDAL® results from the combined concentrations of Rispofren and its major metabolite, 9-hydroxyRispofren . Antagonism at receptors other than D2 and 5HT2 may explain some of the other effects of RISPERDAL®.